The history and contemporary challenges of the US food and drug administration

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 1-16

  Borchers, Andrea T ^a   Hagie, Frank ^b   Keen, Carl L ^c   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AirMD   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adulteration; Food, Drug, and Cosmetic Act; pharmaceutical industry; regulatory agencies

Indexed keywords

BIOLOGICAL PRODUCT; DRUG;

ARTICLE; BEVERAGE; CONSUMER; DRUG LEGISLATION; DRUG QUALITY; FOOD AND DRUG ADMINISTRATION; FOOD QUALITY; GOVERNMENT REGULATION; HISTORY; HUMAN; LANGUAGE; LEADERSHIP; LITERATURE; MEDICAL INSTRUMENTATION; MEDLINE; PUBLIC HEALTH SERVICE; RESPONSIBILITY; SAFETY; UNITED STATES;

CRIME; DRUG APPROVAL; DRUG INDUSTRY; FOOD CONTAMINATION; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33947188198     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.006     Document Type: Article

References (54)

1. Available at:. US Food and Drug Administration. Accessed. Milestones in US food and drug law history (January 12, 2006). http://www.fda.gov/opacom/backgrounders1_rd/miles.html
2. Hutt P.B., and Hutt II P.B. A history of government regulation of adulteration and misbranding of food. Food Drug Cosmetic Law J. 39 (1984) 2-73
3. Janssen W.F. America's first food and drug laws. FDA Consum. 9 (1975) 12-19
4. Hart F.L. A history of the adulteration of food before 1906. Food Drug Cosmetic Law J. (1952) 5-22
5. Young J.H. This greasy counterfeit. Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ 66-94
6. Young J.H. Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ
7. Young J.H. A "murderous traffic". Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ 3-17
8. Young J.H. Progress toward a law. Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ 146-173
9. Hilts P.J. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY
10. Young J.H. A broad concern brought before the Congress. Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ 40-65
11. Hilts P.J. The progressive era. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY 35-55
12. Available at:. Lewis C. The "Poison Squad". Accessed. The beginnings of food and drug regulation in the US (January 17, 2007). http://www.foodreference.com/html/artpoison
13. Stirling D.A. Profiles in toxicology: Harvey W. Wiley. Toxicol Sci. 67 (2002) 157-158
14. Young J.H. Combining and crusading for a law. Pure Food: Securing the Federal Food and Drugs Act of 1906 (1989), Princeton University Press, Princeton, NJ 174-203
15. Available at:. US Food and Drug Administration. Accessed. Activists in the 1906 Pure Food and Drug Act legislative campaign and their successor and successor organizations (January 6, 2006). http://www.fda.gov/oc/history/activists.html
16. Available at:. US Food and Drug Administration. Accessed. Commissioners and their predecessors (January 12, 2006). http://www.fda.gov/oc/commissioners/default.html
17. Hilts P.J. The law succeeds, and fails. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY 56-71
18. Kay G. Healthy public relations: The FDA's 1930 legislative campaign. Bull Hist Med. 75 (2001) 446-487
19. Hilts P.J. Capitalism in crisis. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY 72-94
20. Available at:. US Food and Drug Administration. The story of the laws behind the labels. Part II. Accessed. The federal Food, Drug, and Cosmetic Act (January 12, 2006). http://www.cfsan.fda.gov/lrd/historyla.html
21. December 20. Anderson P.Y. Lydia Pinkham and other Washingtonians. The Nation (1933) 137
22. Available at:. US Food and Drug Administration. The story of the laws behind the labels. Part III. 1962 Drug Amendments. Accessed (January 12, 2006). http://www.cfsan.fda.gov/1rd/historylb.html
23. Hilts P.J. The grand bargain. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY 129-143
24. Hilts P.J. Thalidomide. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred A. Knopf, New York, NY 144-165
25. Available at:. Commission on Dietary Supplements. Background on dietary supplements. Accessed (January 12, 2006). http://www.health.gov/dietsupp/ch2.htm
26. Hilts P.J. The limits of policy. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (2003), Alfred Knopf, New York, NY 202-209
27. Available at:. US Food and Drug Administration. FDA's Mission Statement. Accessed (January 6, 2006). http://www.fda.gov/opacom/morechoices/mission.html
28. Seiguer E., and Smith J.J. Perception and process at the Food and Drug Administration: Obligations and trade-offs in rules and guidances. Food Drug Law J. 60 (2005) 17-32
29. vii. Meldrum M.L. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematol Oncol Clin North Am. 14 (2000) 745-760
30. Doll R. Controlled trials: The 1948 watershed. BMJ 317 (1998) 1217-1220
31. Ley Jr. H.L. Hearing procedure for refusal or withdrawal of approval of new drug applications and for issuance, amendment, or repeal of antibiotic drug regulations: Interpretative description of adequate and well-controlled clinical investigations. Fed Regist. 34 (1969) 14596-14598
32. Edwards C.C. Hearing regulations and regulations describing scientific content of adequate and wellcontrolled scientific investigations. Fed Regist. 35 (1970) 7250-7253
33. Available at:. US Food and Drug Administration. Guidance for industry. Providing clinical evidence of effectiveness for human drug and biological products. Accessed (February 27, 2006). http://www.fda.gov/cder/guidance/1397nl.pdf
34. Katz R. FDA: Evidentiary standards for drug development and approval. NeuroRx. 1 (2004) 307-316
35. Avorn J. FDA standards-good enough for government work?. N Engl J Med. 353 (2005) 969-972
36. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: New estimates of drug development costs. J Health Econ. 22 (2003) 151-185
37. Available at:. Public Citizen. Tufts Drug Study sample is skewed: True figure of R&D costs likely is 75 percent lower. Accessed (September 9, 2006). http://www.publiccitizen.org/pressroom/release.cfmID=954
38. Available at:. Gilbert J., Henske P., and Singh A. Rebuilding big pharma's business model. Accessed. In vivo: The Business and Medicine Report (September 9, 2006). http://www.bain.com/bainweb/PDFs/cms/Marketing/rebuilding_big_pharma.pdf
39. Angell M. The pharmaceutical industry-to whom is it accountable?. N Engl J Med. 342 (2000) 1902-1904
40. Available at:. Eisenberg R.S. The role of FDA in innovation policy. Accessed (January 6, 2007). http://www.utexas.edu/law/academica/centers/clbe/assets/FDAinnovation_draft.pdf
41. Available at:. US Food and Drug Administration. A brief history of the Center for Drug Evaluation and Research. Accessed (January 27, 2006). http://www.fda.gov/cder/about/history/Histext.htm
42. US General Accounting Office. Food and Drug Administration. Effect of user fees on drug approval times, withdrawals, and other agency activities: 36 (2002), US General Accounting Office, Washington, DC
43. Berndt E.R., Gottschalk A.H., Philipson T.J., and Strobeck M.W. Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov. 4 (2005) 545-554
44. Suppl Web Exclusives:W3-618-W3-624. Carpenter D., Chernew M., Smith D.G., and Fendrick A.M. Approval times for new drugs: Does the source of funding for FDA staff matter?. Health Aff (Millwood) (2003)
45. Suppl Web Exclusives:W4-Sl-W4-S2. Olson M.K. Explaining reductions in FDA drug review times: PDUFA matters. Health Aff (Millwood) (2003)
46. Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 329 (2004) 1308
47. Politics trumps science at the FDA. Lancet 366 (2005) 1827
48. Burstein P.D. A sad day for science at the FDA. N Engl J Med. 353 (2005) 2619-2621
49. Kling J. Pessimistic response to FDA leadership change [published correction appears in Nat Biotechnol. 2006;24:220]. Nat Biotechnol. 23 (2005) 1325
50. Lenzer J. FDA is incapable of protecting US "against another Vioxx.". BMJ. 329 (2004) 1253
51. Nelson R. Continuing concerns over acting FDA commissioner. Lancet Oncol. 6 (2005) 827
52. What is going on at the FDA?. Lancet 366 (2005) 1137
53. Kennedy D. Chess game at the FDA. Science 310 (2005) 589
54. Wadman M. Many issues in store for new FDA commissioner. Nat Rev Drug Discov. 4 (2005) 871-872